Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is an inflammatory sinonasal disease characterized by the presence of polyps in patients with the diagnosis of CRS. Most nasal polyps (NPs) in Caucasian patients with CRSwNP are eosinophilic, a state that is frequently associated with asthma. 1 In contrast, recent studies, including ours, have demonstrated that more than half of the patients with CRSwNP in East Asian countries presented with noneosinophilic inflammation. [2] [3] [4] Although genetic and/or environmental factors may contribute to the heterogeneity of CRSwNP, the mechanisms underlying the persistent and exaggerated inflammation in CRSwNP are not fully defined.
Eosinophilic CRSwNP is characterized by T H 2-skewed eosinophilic inflammation with local IgE hyperproduction and displays a poor surgical outcome. 1, [5] [6] [7] Various inflammatory cells are implicated in the development of eosinophilic inflammation in CRSwNP, such as dendritic cells, 8, 9 basophils, 10 innate type 2 lymphoid cells, 11, 12 and lymphocytes. 13, 14 Recently, we and others have reported an accumulation of mast cells, particularly activated mast cells in CRSwNP, which correlates with eosinophilia in polyps. 15, 16 Furthermore, locally secreted IgE can bind to mast cells in polyps and lead to mast cell activation on allergen exposure. 16, 17 These findings raise the possibility that mast cells may be critical in mediating environmental antigen-induced pathogenesis of CRSwNP. Indeed, a recent study showed that mast cell deficiency may limit the development of CRS in an ovalbumin (OVA)-induced murine CRS model. Recent discoveries have illustrated that aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, in mast cells can mediate environmental factor-induced cell differentiation, growth, and functions. [19] [20] [21] Of interest, exposure of mouse and human mast cells to AhR ligands exacerbated allergen-induced, IgE-mediated oxidative stress, reactive oxygen species (ROS) generation, and calcium (Ca 21 )-dependent activation of mast cells. 21 AhR is widely expressed in barrier organs such as skin, gut, and lung 22 and was originally characterized for its function in metabolizing environmental pollutants such as dioxin and many other polycyclic aromatic hydrocarbons. 23 Upon ligand binding, AhR translocates from cytosol to the nucleus, leading to changes in target gene transcription (eg, cytochrome P450 family 1 subfamily A member 1 [cyp1a1] and cytochrome P450 family 1 subfamily B member 1 [cyp1b1]) and various immunotoxicological effects. 24, 25 However, recent studies found that AhR can also sense kynurenine (KYN) or other endogenous tryptophan metabolites generated by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), 26, 27 and regulate mast cell activation. 27 However, the potential role of KYN/AhR signaling in regulating mast cell activation in CRSwNP has not yet been studied.
The multifunctional Ca 21 /calmodulin-dependent protein kinase II (CaMKII) is within one of the downstream signaling pathways activated by ROS. 28 CaMKII can be activated by oxidization at methionines 281/282 in the regulatory domain with ROS, leading to a persistently oxidative activation of CaMKII (oxidized calmodulin-dependent protein kinase II [ox-CaMKII]). 29 Increased ox-CaMKII was observed in the airway epithelium of patients with asthma and has been associated with asthma. [30] [31] [32] We have recently demonstrated that ox-CaMKII in mast cells play a critical role in regulating mast cell activation and the exacerbation of cockroach allergeninduced lung inflammation. 33 However, it remains unknown whether ox-CaMKII regulates chronic inflammation in CRSwNP.
The present study sought to determine the role of the KYN/AhR axis in promoting allergen-induced IgE-mediated immune responses in mast cells in the development of CRSwNP. We have made several novel findings, including increased levels of indoleamine 2,3-dioxygenase 1(IDO1)/TDO1/KYN and activated AhR signaling in mast cells of NP tissues from CRSwNP and AhR-regulated mast cell ROS generation and oxidation of CaMKII. Most importantly, we found an increased ox-CaMKII in CRSwNP, and that ox-CaMKII plays a critical role in allergen-induced, KYN-potentiated mast cell activation. Findings from these studies suggest that the KYN/AhR axis in mast cells may contribute to the distinct patterns of inflammation and possible clinical features observed in patients with eosinophilic CRSwNP.
METHODS

Study subjects
The study was approved by the Ethics Committee of Tongji Hospital of Huazhong University of Science and Technology and was conducted with written informed consent from the patients. The clinical data of patients are summarized in Table E1 in this article's Online Repository at www.jacionline. org. The diagnosis of CRSwNP was made according to the current European Position Paper on Rhinosinusitis and Nasal Polyps and American guidelines. 34, 35 CRSwNP is classified as eosinophilic when the percentage of eosinophils in the tissue exceeds 10% of total infiltrating cells as defined by our previous study. 3 Control subjects are those undergoing septoplasty because of anatomical variations without sinonasal diseases. Polyp tissues from patients with CRSwNP and the inferior turbinate mucosa from control patients were harvested during surgery. Oral glucocorticoid and intranasal steroid spray were discontinued at least 3 months and 1 month before surgery, respectively. Subjects who had antrochoanal polyps, cystic fibrosis, fungal sinusitis, primary ciliary dyskinesia, or gastroesophageal reflux disease were excluded from the study.
Histological analysis
Immunohistochemical and immunofluorescence staining was performed as previously described. 3 Primary antibodies (see Table E2 in this article's Online Repository at www.jacionline.org) and additional information regarding immunohistochemistry are provided in this article's Online Repository at www.jacionline.org.
RT-PCR
Quantitative RT-PCR was performed with appropriate primers (see Table E3 in this article's Online Repository at www.jacionline.org) as previously reported. 3 Additional information is provided in this article's Online Repository at www.jacionline.org.
HPLC
Sample processing and HPLC analysis was performed as previously described with minor modifications. 36, 37 Additional information is provided in this article's Online Repository at www.jacionline.org.
Mice
C57BL/6, AhR-null (wild-type [WT] .129-Ahr tm1Bra /J), and Kit W-sh/W-sh mice were purchased from the Jackson Laboratory (Bar Harbor, Me). ROS-resistant CaMKIId (MMVVd) mice were generated by Dr Mark Anderson's laboratory at the Johns Hopkins University School of Medicine. Age-and sex-matched mice were used as controls. These mice were maintained under specific-pathogen-free conditions. All experiments were approved by the Animal Care and Use Committee at Johns Hopkins University School of Medicine. 
Measurements of degranulation and histamine release
Degranulation was first monitored by time-lapse microscopy. Approximately 5.0 3 10 4 BMMCs previously sensitized with 1 mg/mL of anti-OVA IgE (E-C1, Chondrex, Redmond, Wash) were plated on fibronetic (Thermo Fisher, Halethorpe, Md)-coated Lab-Tek chambered cover glass (Thermo Fisher) in Tyrode's buffer supplemented with 8 mg/mL of avidin-sulforhodamine 101 (Av.SRho, Sigma-Aldrich, St Louis, Mo). The cells were incubated at 378C for 30 minutes and then stimulated with 10 mg/mL of OVA. Fluorescence was acquired every 2.3 seconds using Zeiss confocal microscope and AxioVision 4.2 software in an environmental chamber (378C and 5% CO 2 ). Mast cell degranulation was quantified by flow cytometric analysis for the expression of CD107a/LAMP-1 (1:200, clone eBio1F4B, ThermoFisher, Halethorpe, Md). 38 Degranulation was also quantified by measuring b-hexosaminidase release in the culture supernatants as previously described. 33 Histamine release was assessed by using automated fluorimetry as previously described. 39 
ELISA
Supernatants were collected for the measurement of IL-5 (eBiosciences), IL-13 (eBiosciences), and IL-33 (R&D Systems, Minneapolis, Minn) using ELISA kits according to the manufacturer's instructions.
Tissue IgE measurement
Tissue samples were weighed and homogenized and the supernatants were harvested. The levels of total IgE in supernatants were detected by using the ImmunoCAP system (Phadia, Uppsala, Sweden). 16 Mast cell engraftment into mast cell-deficient mice BMMCs cultured from AhR 2/2 and WT female mice were engrafted into the mast cell-deficient mice (Kit W-sh/W-sh ) as described elsewhere. 40 A total of 1.0 3 10 6 BMMCs were engrafted into the ears by intradermal injection. After 6 weeks, mast cells' engraftment was assessed by Toluidine blue staining.
Passive cutaneous anaphylaxis
Passive cutaneous anaphylaxis (PCA) was performed as previously described. 33 Additional information is provided in this article's Online Repository at www.jacionline.org.
Western blotting
Equal amounts of proteins were separated on a 12% (w/v) Tris-Glycine Gel (Thermo Fisher) in NuPAGE MES SDS Running Buffer (Thermo Fisher). The separated proteins were transferred onto polyvinylidene difluoride membranes (Thermo Fisher) and probed with anti-IDO1 (1:500; Abcam, Cambridge, UK), anti-ox-CaMKII (1:1000; Millipore, Billerica, Mass), or antitotal CaMKII (1:1000, Abcam) overnight at 48C. Blots were then probed with goat antirabbit (Santa Cruz Biotechnology, Santa Cruz, Calif) or goat antimouse IgG-horseradish peroxidase (Santa Cruz Biotechnology) for 1 hour at 378C. Detection was performed by using the ECL Western blotting detection system (GE Life Sciences, Pittsburgh, Pa).
Detection of mitochondrial superoxide in BMMCs
For mitochondrial superoxide staining, BMMCs previously sensitized with 1 mg/mL of anti-OVA IgE were incubated on fibronectin-coated glass slides with 5 mM MitoSOX (Thermo Fisher) and 100 nM MitoTracker Green (Thermo Fisher) for 30 minutes at 378C in Tyrode's buffer. Cells were washed and challenged with 10 mg/mL of OVA for 30 minutes at 378C in Tyrode's buffer. After challenge, cells were mounted in warm buffer for imaging.
Measurement of intracellular ROS production by flow cytometry
Intracellular ROS production in BMMCs was measured by flow cytometry with CM-H2DCFDA (5 mM, ThermoFisher) as described previously. 21, 33 Intracellular calcium measurement Intracellular calcium was measured as described previously. 21, 33 In brief, BMMCs sensitized with anti-OVA IgE in the presence or absence of 50 mM of KYN were loaded with 2.5 mM of Fluo-4-acetomethoxy ester (ThermoFisher) for 1 hour in the dark at 378C and then challenged with 10 mg/mL of OVA. Fluoresecent signals at 488 nm excitation were imaged continuously for 90 to 120 seconds to detect intracellular free calcium.
Statistical analysis
The expression data generated from human sinonasal mucosal samples are presented in dot plots. Symbols represent individual samples, horizontal bars represent medians, and error bars show interquartile ranges. A Kruskal-Wallis H test was used to detect significant intergroup variability, and a Mann-Whitney U test was used for between-group comparison. The Spearman rank test was used for correlations. Statistical analysis was performed with SPSS software (SPSS, Chicago, Ill). For mouse studies, the significance of differences among groups was determined by 1-way ANOVA (nonparametric test) using GraphPad Prism statistical software program (GraphPad, Inc, La Jolla, Calif). When 2 groups were compared, an unpaired, 2-tailed Student t test was used. A P value of less than .05 was considered statistically significant.
RESULTS
Increased levels of IDO1, tryptophan2,3-dioxygenase, and KYN in CRSwNP
AhR signaling can be activated by KYN or other endogenous tryptophan metabolites generated by IDO1 and tryptophan2,3-dioxygenase (TDO2). 26, 27 We first assessed whether the expression of IDO1 and TDO2 was increased in patients with CRSwNP. Compared with controls, NP tissues from patients with eosinophilic and noneosinophilic CRSwNP showed increased mRNA expression of IDO1 and TDO2 (Fig 1, A) . Compared with noneosinophilic polyps, eosinophilic polyps showed a further increase in the mRNA expression of IDO1. Similar patterns were observed for IDO1-and TDO2-positive cells in lamina propria of sinonasal mucosa as analyzed by immunostaining (Fig 1, B) ; both eosinophilic and noneosinophilic polyps had a greater number of IDO1-and TDO2-positive cells as compared with controls (Fig 1, C) . The increased expression of IDO1 in CRSwNP was further confirmed by Western blot (see Fig E1 in this article's Online Repository at www.jacionline. org). We next analyzed whether these increased levels of IDO1 and TDO2 can lead to the generation of KYN by measuring levels of KYN in NP tissues with HPLC. Consistent with the expression of IDO1 and TDO2, the levels of KYN were much higher in both eosinophilic and noneosinophilic polyps when compared with controls, with a further increase in eosinophilic polyps compared with noneosinophilic polyps (Fig 1, D) . Consistent with our previous reports, 15, 16 we found that the number of activated mast cells in lamina propria (Fig 1, E and F) , but not in epithelium (Fig 1, F) and epithelium (Fig 1, G) of NPs and control tissues. H, Local total IgE levels. Eos CRSwNP, Eosinophilic CRSwNP; Epi, epithelium; non-Eos CRSwNP, noneosinophilic CRSwNP; LP, lamina propria. (Fig 1, E and G) , and local levels of local IgE (Fig 1, H) were markedly increased in eosinophilic polyps compared with noneosinophilic polyps and controls. Furthermore, there was a significant correlation between activated mast cells in lamina propria and levels of KYN (see Fig E2, A, in this article's Online Repository at www.jacionline.org) and local IgE (Fig E2, B) in eosinophilic polyps. Taken together, these data demonstrated increased levels of KYN, activated mast cells, and local IgE in eosinophilic polyps.
Activated AhR signaling in CRSwNP
Given the increased KYN in CRSwNP, we tested whether KYN can activate AhR signaling, particularly in mast cells, in CRSwNP. We first detected AhR 1 cells and their relationship with mast cells in polyps. We found that about an average of 75% and 71% of AhR 1 cells are tryptase 1 mast cells in eosinophilic and noneosinophilic polyps, respectively (Fig 2,  A) . We further confirmed the predominant expression of AhR in mast cells in polyps by coimmunoflorescence staining for AhR and CD117 (c-Kit) (Fig 2, B) . In addition, we detected the expression of AhR target genes in the sinonasal mucosa, including the canonical AhR target genes cyp1a1 and cyp1b1 (Fig 2, C) . Both eosinophilic and noneosinophilic polyps showed increased mRNA expression for cyp1a1 and cyp1b1 when compared with controls (Fig 2, C) . Compared with noneosinophilic polyps, eosinophilic polyps showed a further increase in the mRNA expression of cyp1a1 (Fig 2, C) . The increased expression was further confirmed specifically in mast cells by coimmunofluorescent staining (Fig 2, D and F) . CRSwNP showed an increased percentage of cyp1a1 1 (Fig 2, E ) or cyp1b1 1 (Fig 2, G) mast cells over total mast cells in lamina propria as compared with controls, with a further increase in eosinophilic CRSwNP compared with noneosinophilic CRSwNP. Overall, these data suggest an increased activation of AhR signaling in mast cells in NPs.
KYN potentiates allergen-driven activation of AhR signaling in mast cells
To determine whether KYN can potentiate allergen-induced mast cell activation through AhR signaling in eosinophilic CRSwNP, mouse BMMCs were sensitized and challenged using our well-established protocol as illustrated in Fig 3, A. 21,33 (Fig 2, D) or cyp1b1 (Fig 2, F) (green) with tryptase (red) in human NP tissues. Percentage of cyp1a1 1 (Fig 2, E BMMCs were isolated and identified by flow cytometry with antibodies against both c-Kit and FcεRI (Fig 3, B) . The mRNA expression of AhR, cyp1a1, and cyp1b1 was significantly increased in the OVA-activated BMMCs, which could be further enhanced by KYN (Fig 3, C-E) . These data support a role for KYN in potentiating allergen-activated AhR signaling in mast cells.
KYN enhances allergen-induced mast cell ROS generation, intracellular Ca 21 levels, and mast cell activation ROS are important mediators that may contribute to oxidative damage and chronic inflammation in allergic diseases. [41] [42] [43] [44] Increased ROS have also been reported in the sinus tissues of patients with CRSwNP. 34, 45, 46 To detect whether KYN can enhance allergen-activated ROS generation in mast cells, we measured intracellular ROS production in BMMCs. As shown in Fig 4, A, KYN promoted OVA-induced intracellular ROS generation in BMMCs, but the increased ROS was not observed in AhR-deficient (AhR 2/2 ) BMMCs (Fig 4, B) . Next, we measured the mitochondrial ROS in these BMMCs using MitoSOX (Fig 4, C) . We found higher levels of mitochondrial ROS in OVA-treated BMMCs compared with controls, and the increase was further enhanced by KYN (Fig 4, D) . Similar to intracellular ROS, the KYN-potentiated mitochondrial ROS increase was not observed in AhR 2/2 BMMCs. These findings support a view that KYN may potentiate ROS production, particularly mitochondrial ROS in allergen-activated mast cells through AhR.
We had previously shown that the generation of intracellular ROS was dependent on increased intracellular calcium [Ca 21 ]i. 21 To further determine whether KYN-increased ROS production in BMMCs is associated with changes in (Fig 4, E) , mean fluorescent intensity (Fig 4,  F) , and total calcium response (Fig 4, G) . Treatment with KYN further enhanced OVA-induced levels of [Ca 21 ]i. Using the same protocol, we also examined whether KYN can enhance allergen-induced mast cell activation. We first investigated the spatiotemporal dynamics of mast cell degranulation by using a soluble fluorochrome-labeled avidin (sulforhodamine BMMCs; however, this response was significantly weakened (Fig 4, I) . Furthermore, staining of CD107a/LAMP-1 for degranulation in BMMCs was quantified by flow cytometry analysis (Fig 4, J) . BMMCs from AhR 2/2 mice showed reduced expression of CD107a/LAMP-1 after OVA challenge when compared with those from WT mice. We also quantified mast cell degranulation using b-hexosaminidase release assays. Compared with unchallenged, OVA-activated BMMCs showed elevated levels of b-hexosaminidase, which was further strengthened by KYN (Fig 4, K) . Moreover, compared with WT, AhR 2/2 mast cells had lower levels of b-hexosaminidase following OVA or OVA with KYN treatment (Fig 4, K) . Of interest, similar results were obtained for histamine release (Fig 4, L) and IL-13 secretion (Fig 4, M) . These data further support the previous findings that KYN can potentiate allergen-activated mast cell activation.
AhR is required for IgE-mediated and mast-celldependent allergic responses
To determine whether mast cell-expressed AhR is required for IgE-mediated and mast-cell-dependent allergic responses, we engrafted BMMCs from WT and AhR 2/2 mice into the ears of mast cell-deficient mice (Kit W-sh/W-sh ) using the protocol illustrated in Fig 5, A. 40 Mast cell engraftment was confirmed by Toluidine blue staining after 6 weeks (Fig 5, B and C). Compared with Kit W-sh/W-sh mice without engraftment, Kit W-sh/W-sh mice engrafted with WT BMMCs showed increased OVA-induced PCA (Fig 5, D) . Of interest, Kit W-sh/W-sh mice engrafted with AhR 2/2 BMMCs showed significant reduction in OVA-induced PCA when compared with those engrafted with WT BMMCs. Thus, these data suggest that mast cell-expressed AhR is required for IgE-mediated and mast-cell-dependent allergic responses.
Patients with CRSwNP showed increased oxidative activation of CaMKII
We have recently demonstrated that ox-CaMKII in mast cells promoted allergen-induced mast cell activation and cockroach allergen-induced lung inflammation. 33 To test whether ox-CaMKII is also involved in KYN/AhR signaling-mediated mast cell activation in CRSwNP, we first measured ox-CaMKII expression in the polyp tissues (Fig 6, A) . Immunohistochemical staining showed that ox-CaMKII was mainly expressed in airway epithelial cells and infiltrating cells in sinonasal mucosa. Both eosinophilic and noneosinophilic polyps had greater numbers of ox-CaMKII-positive cells in lamina propria when compared with those from controls (Fig 6, B) . The increased expression of ox-CaMKII in polyp tissues was further confirmed by Western blot (Fig 6, C) . We next studied the expression of ox-CaMKII specifically on mast cells by coimmunofluorescence staining for ox-CaMKII and tryptase (Fig 6, D) . We found that the percentage of ox-CaMKII 1 tryptase 1 cells overall total mast cells in lamina propria was much higher in eosinophilic and noneosinophilic polyps as compared with controls, with a further increase found in eosinophilic polyps (Fig 6, E) . (Fig 3, C) , cyp1a1 (Fig 3, D) , and cyp1b1 (Fig 3, E) were quantified by using PCR in OVA-sensitized and -challenged mast cells with or without KYN. Results are expressed as fold changes over medium in expression of target genes to the internal control b-actin. Data are expressed as mean 6 SEM of 2 independent experiments. *P < .05, **P < .01.
AhR regulates allergen-activated mast cell activation through ox-CaMKII
We further examined whether the differential expression of ox-CaMKII in polyp's mast cells is regulated by AhR. We specifically examined ox-CaMKII expression in OVA-activated WT and AhR 2/2 BMMCs. BMMCs were sensitized and challenged following the previous protocol in Fig 3, A. Compared with unchallenged, OVA-challenged BMMCs showed increased ox-CaMKII, which was further enhanced by KYN (Fig 7, A  and B) . However, the increased ox-CaMKII was not seen in AhR 2/2 BMMCs (Fig 7, A and B) . No significant difference was detected for total CaMKII among all these groups (Fig 7,  C) . Next, we examined whether ox-CaMKII mediated mast cell activation. Using the same approach as above in Fig 4, H, we investigated the spatiotemporal features of mast cell degranulation by using Av.SRho 47, 48 (Fig 7, D) . Compared with WT, MMVVd BMMCs showed weakened intensities in Av.SRho staining on the surface of the cells (Fig 7, E) . We then measured cytokines released from BMMCs from WT and ROS-resistant CaMKII MMVVd mice (MMVVd). Compared with control, increased levels of IL-5, IL-13, and IL-33 were observed in OVA-activated BMMCs (Fig 7, F) . However, the increase was markedly suppressed in BMMCs from MMVVd. These findings indicate that AhR regulates allergen-induced mast cell activation though ox-CaMKII.
CaMKII inhibitor suppresses KYN-potentiated allergen-induced mast cell activation
KN-93 can suppress OVA-induced asthma. 30 To further explore the possible role of CaMKII in mast cell activation, we used KN-93 to investigate whether inhibition of CaMKII can abrogate the KYN-promoted mast cell activation induced by OVA challenge following the protocol described in Fig 3, A. We (Fig 4, A) and AhR-null (Fig 4, B) mouse BMMCs in the presence or absence of KYN. C, Representative MitoTracker or MitoSOX staining of these anti-OVA IgE-sensitized and OVA-challenged BMMCs derived from WT and AhR-deficient mice. Original magnification, 320. D, Quantitative data for immunofluorescence staining. E and F, Representative Fluo-4 fluorescence heat map images (Fig 4, E) and imaging traces (Fig 4, F) (Fig 4, H) and mean curves of Av.SRho MFI (Fig 4, I ) of single anti-OVA IgE-sensitized BMMC activated with OVA. J, Expression of CD107a/LAMP-1 detected by flow cytometry analysis. K-M, Mast cell activation was assessed by b-hexosaminidase (Fig 4, K) , histamine release (Fig 4, L) , and IL-13 (Fig 4, M) . Data are expressed as mean 6 SEM of 3 independent experiments. AUC, Area under the curve; MFI, mean fluorescent intensity. *P < .05, **P < .01. found that KYN can enhance OVA-activated mast cell activation including degranulation (Fig 8, A) , histamine release (Fig 8, B) , and IL-13 production (Fig 8, C) . However, as expected, the KYN-enhanced mast cell activation was significantly inhibited when these BMMCs were pretreated with KN-93 (Fig 8, A-C) . Furthermore, we examined whether KN-93 affects KYN-potentiated OVA-induced PCA following the protocol described in Fig 8, D . The KYN potentiated OVA-induced (Fig 7, B) and total CaMKII (Fig 7, C) protein levels. D and E, Representative time-lapse (Fig 7, D) and mean curves of Av.SRho MFI (Fig 7, E) of single anti-OVA IgE-sensitized BMMC activated with OVA. F, Cytokine release from mast cells was assessed by IL-5, IL-13, and IL-33. MFI, mean fluorescent intensity. Data are expressed as mean 6 SEM from 2 independent experiments. *P < .05, **P < .01. (Fig 8, A) , histamine (Fig 8, B) , and IL-13 (Fig 8, C) . Data are expressed as mean 6 SEM from 2 independent experiments. D, Experimental setup for KN-93 inhibition of KYN-potentiated IgE-mediated mast cell activation. E, Representative images of Evans blue-stained extravasation into skin. F, Quantification of the extravasation of Evans blue leakage into the skin (Fig 8, E , n 5 3-4/group). G, Mechanistic model of the KYN/AhR axis in regulating mast cell activation through ROS and ox-CaMKII in the development of CRSwNP. EB, Evan's Blue; LTC4, Leukotriene C 4 ; PDG2, prostaglandin D2.
PCA, which was significantly suppressed when mice were pretreated with KN-93 (Fig 8, E and F) . These findings further supported that CaMKII may be crucial for the KYN-potentiated allergen-induced mast cell activation and allergic responses.
DISCUSSION
Eosinophilic CRSwNP is characterized by T H 2-biased inflammation with high concentrations of IgE against different allergens found in polyps. 49 The hyperproduced IgE can sensitize and activate resident mast cells, leading to mast cell activation and subsequent eosinophilic inflammation in CRSwNP. 15, 16 Studies from our research group have illustrated that activated mast cells are increased in patients with eosinophilic CRSwNP, which are positively correlated with levels of local IgE. 16 Thus, in this study, we extended our previous work to test our novel hypothesis that endogenous tryptophan metabolites function as AhR ligands to promote allergen-induced, IgE-mediated activation of mast cells in eosinophilic CRSwNP, and explored their possible mechanisms.
It is well established that the activation of IDO1 and TDO2 and the generation of KYN metabolites are critical in modulating the activation of various innate and adaptive immune cells through different biochemical mechanisms. 50 KYN is a novel endogenous ligand for AhR. The downstream events of AhR activation appear to occur in a cell-type and immune context-dependent manner. For example, KYN-activated AhR drives naive CD4
1 T-cell differentiation into immunosuppressive Foxp3 1 regulatory T cells rather than proinflammatory T H 17 cells, 51 representing a potent inhibitory signaling for T-cell-mediated immune responses. In contrast, studies from our laboratory have demonstrated that AhR ligands (eg, FICZ 21 and KYN 27 ) potentiate IgE-mediated mast cell activation and subsequently promote inflammatory immune responses. Because of those fundamental differences in findings, it is essential to further explore the mechanisms underlying the effect of KYN/AhR signaling on mast cell activation in human diseases. In this study, we provide novel evidence to support a potential role of KYN-AhR signaling to promote allergen-induced, IgE-mediated activation of mast cells in eosinophilic CRSwNP. 16, 18 We found that AhR was predominantly expressed in mast cells in NPs. Most importantly, we observed differences in the levels of KYN and AhR downstream target genes cyp1a1 and cyp1b1 in NP tissues between eosinophilic and noneosinophilic polyps. Furthermore, there was a significant correlation between the levels of KYN and local IgE and the number of activated mast cells in eosinophilic polyps. Therefore, it is tempting to speculate that KYN-AhR signaling is crucial in determining mast cell activation in eosinophilic polyps with high levels of local IgE, which may contribute to the different patterns of inflammation and distinct clinical features between eosinophilic and noneosinophilic CRSwNP. Indeed, numerous studies have demonstrated significant differences in clinical features, patterns of inflammation, and tissue remodeling between eosinophilic and noneosinophilic CRSwNP. 16, 52, 53 We have made great efforts to identify the major risk factors that may contribute to the differences. In particular, we have previously demonstrated differences in the numbers of active mast cells and levels of local total and allergen-specific IgE. 16 Also, we have displayed differences in dendritic cells and T-cell subtypes. 14, 54 In this study, we made a new discovery that the AhR signalingpotentiated mast cell activation may be different between eosinophilic and noneosinophilic CRSwNP. Although results from previous and current studies did not show any differences in activated mast cells and local IgE, 16 significant differences were noted for IDO1, TDO2, KYN, and AhR downstream target genes cyp1a1 and cyp1b1 between noneosinophilic CRSwNP and controls. These findings raise the possibility that the KYN-AhR signaling pathway plays a role in contributing to the different patterns of inflammation between noneosinophilic CRSwNP and controls, but may not be through mast cells. Thus, it is tempting to speculate that the KYN-AhR signaling pathway is required for CRSwNP but may play a distinct role in eosinophilic or noneosinophilic CRSwNP depending on its local immune cells (eg, mast cells vs other cell types).
We have previously demonstrated that AhR signaling mediated mast cell activation. 21 In this study, we provided additional evidence with the spatiotemporal dynamics of mast cell degranulation in live cells from WT and AhR 2/2 mice by Av.SRho, a probe that selectively stains mast cell granules. 47, 48, 55 This method made it possible to see that in the early step of mast cell granule exocytosis, the granule matrix is externalized and immediately bound by Av.SRho. We found that AhR 2/2 BMMCs showed weakened Av.SRho staining on the surface of the cells after OVA stimulation and challenge compared with WT. The results were further supported by flow cytometry analysis of CD107a/LAMP-1. Most intriguingly, to determine the significance of AhR expressed on mast cells in allergen-induced allergic responses, we engrafted BMMCs from WT and AhR 2/2 mice into Kit W-sh/W-sh mice and tested for PCA analysis. We noted that Kit W-sh/W-sh mice engrafted with AhR 2/2 BMMCs showed significant reduction of OVA-induced PCA when compared with those engrafted with WT BMMCs, suggesting that the mast cell-expressed AhR may be required for IgE-mediated and mast-cell-dependent allergic responses.
We next explored the underlying mechanisms regarding the AhR signaling-promoted, IgE-mediated mast cell activation. Our data provided evidence that the AhR ligand-activated mast cell activation is dependent on ROS generation and intracellular Ca 21 . Particularly, AhR ligands are able to increase ROS generation as a consequence of the increased expression of AhR target genes (eg, cyp1a1) 21, 56 and several membrane nicotinamide adenine dinucleotide phosphate-oxidase complexes, p40phox. 57 Increased ROS generation in the sinus tissues of patients with CRSwNP has also been reported. 45, 46 Our present studies showed that OVA induced higher levels of intracellular ROS, which was further enhanced by KYN treatment in WT, but not AhR 2/2 mast cells. A similar pattern to that of intracellular ROS was discovered for the mitochondrial ROS in mast cells. These findings support that KYN may potentiate ROS generation in allergen-activated mast cells through the activation of AhR signaling. To explore the mechanisms underlying ROS generation, we analyzed intracellular Ca 21 , which may contribute to the generation of intracellular ROS. We found that OVA-activated mast cells exhibited elevated levels of intracellular Ca 21 , which was further promoted by KYN. Given that we have previously demonstrated the significant inhibition of the intracellular ROS by the calcium antagonist 2-aminoethoxydiphenyl borate, 21, 33 we conclude that intracellular Ca 21 may play a critical role in the KYN-promoted generation of ROS.
CaMKII is within one of the downstream signaling pathways activated by ROS, 28 and the increased expression of ox-CaMKII has been associated with asthma. [30] [31] [32] Furthermore, our recent studies have indicated a role of ox-CaMKII in modulating allergen-induced mast cell activation and promoting cockroach allergen-induced asthma. 33 In this study, we demonstrated for the first time that AhR regulates oxidative activation of CaMKII through controlling ROS generation, suggesting that CaMKII may be a target of oxidation via AhRand ROS-dependent mechanisms. Of interest, ox-CaMKII was significantly increased, particularly in mast cells of eosinophilic polyps. Our studies provided experimental evidence that ox-CaMKII modulates allergen-induced, and KYN-promoted mast cell activation, including mast cell degranulation, Leukotriene C 4 , histamine release, cytokine production (eg, IL-5, IL-13, and IL-33), and PCA. In addition, previous reports found that KN-93, an inhibitor of CaMKII, 58 can suppress OVA-induced asthma 30 and mast cell activation. 33 Indeed, KYN-potentiated OVA-induced mast cell activation in vitro and PCA in vivo were significantly blocked when CaMKII inhibitor KN-93 was used. Those findings suggest that AhRregulated mast cell activation may be through the regulation of ROS generation and subsequent ox-CaMKII in eosinophilic polyps. KN-93 or targeting on ox-CaMKII has the potential for the treatment of CRSwNP.
In summary, our studies tested the novel hypothesis (Fig 8,  G) that KYN serves as an AhR ligand and promotes allergeninduced, IgE-mediated mast cell activation through the upregulation of ROS generation and oxidative activation of CaMKII and subsequent chronic inflammation in eosinophilic CRSwNP. However, several questions remain to be elucidated in the future, including triggers in inducing the expression of IDO1 and TDO2, and increased levels of KYN in CRSwNP, AhR-regulated mast cell-independent immune response in noneosinophilic CRSwNP, and the mechanisms underlying the ox-CaMKII-mediated mast cell activation. Interestingly, genomic analysis in evaluating nasal and sinus bacterial and fungal microbiomes in CRS has suggested associations between certain microorganisms and CRS. 59 However, there is no publication to show whether those nasal microbiomes contribute to the increased IDO/TDO/KYN and activation of AhR signaling, which is an interesting question and worth of future investigation. In addition, in contrast to Takabayashi et al' s report, 15 our present and previous study demonstrated a significant accumulation of activated mast cells in stroma, but not in glands in eosinophilic NPs. 16 We postulated that the differences in the observed location of mast cells among different studies may be due to differences in the status of mast cell activation or differences in the particular mediators that activate mast cells (eg, inhaled or endogenous). Thus, future studies are clearly needed to investigate the distribution of mast cells and their corresponding phenotypes in polyp tissues of CRSwNP from different ethnic populations. Collectively, these studies could provide a conceptual framework linking the KYN/AhR axis to mast cell activation through regulating ROS generation and oxidative activation of CaMKII and new insights onto the mechanisms that underlie the pathogenic progression of CRSwNP.
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METHODS
Histological analysis
Immunohistochemical and immunofluorescence staining was performed as previously described. E1 Primary antibodies used are listed in Table E2 . Consecutive sections were used to study the relationship between AhR expression and tryptase-positive cells. Immunofluorescence staining was used to show the colocalization of AhR and CD117, tryptase and cyp1a1 and cyp1b1, and ox-CaMKII and tryptase. Mast cells were identified by immunostaining for tryptase. Mast cells were considered as intact if they had discrete, focal, and well-circumscribed immunostaining for tryptase (Fig 1, E) . E1 The degranulated mast cells were identified as cells that have discrete and relatively focal staining, but do not have well-circumscribed immunostaining. In addition, extracellular staining of tryptase is often observed in the area surrounding degranulated cells. 
RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from tissues and reverse-transcribed to cDNA with random hexamer primers following the protocol as previously described. E2 Quantitative PCR assay was performed on the Light-Cycler system (Roche Diagnostics, Mannheim, Germany) with the SYBR Premix Ex Taq kit (TaKaRa Biotechnology, Dalian, China) with appropriate primers (Table E3 ). Relative gene expression was calculated by using the 2 2DD CT method. E2 An inferior turbinate sample from a control was used as a calibrator. Glyceraldehyde 3-phosphate dehydrogenase was used as a housekeeping gene for normalization, and a ''no template'' sample was used as a negative control.
HPLC
Sample processing for HPLC analysis was performed as previously described with minor modification. E3 ,E4 Approximately 50 mg of each tissue sample was weighed and minced using liquid nitrogen. A 250-mL mixture of chloroform, methanol, and water (2:5:2) was added and the samples were vortexed for 1 minute. The samples were then placed at 220 8C for 20 minutes to extract metabolites, followed by centrifugation at 12,000 rpm for 10 minutes. The liquid layer was transferred into a new tube. The residue was extracted with 250 mL of methanol using the homogenizer for 10 minutes followed by centrifugation at 12,000 rpm for 10 minutes. The supernatant was Eos CRSwNP, Eosinophilic CRSwNP; IQR, interquartile range; F, Female; M, male; non-Eos CRSwNP, noneosinophilic CRSwNP. *Atopic status was evaluated using skin prick test with a panel of 16 inhalant allergens common in our region as previously described.
E5
The diagnosis of asthma was based on history and physician's diagnosis according to Global Initiative for Asthma guideline. 
E6
